Compare HUBC & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUBC | CVKD |
|---|---|---|
| Founded | 2017 | 2022 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.0M | 20.7M |
| IPO Year | N/A | 2023 |
| Metric | HUBC | CVKD |
|---|---|---|
| Price | $0.48 | $12.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 2.1M | 43.2K |
| Earning Date | 05-01-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,562,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $8.12 |
| 52 Week High | $14.00 | $22.90 |
| Indicator | HUBC | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 18.98 | 58.77 |
| Support Level | $0.36 | $9.55 |
| Resistance Level | $0.59 | $12.00 |
| Average True Range (ATR) | 0.16 | 0.94 |
| MACD | -0.04 | 0.34 |
| Stochastic Oscillator | 14.51 | 92.92 |
Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.